

# Soluble guanylate cyclase as a novel target for cognition enhancement

Citation for published version (APA):

Nelissen, E. (2022). *Soluble guanylate cyclase as a novel target for cognition enhancement*. [Doctoral Thesis, Maastricht University]. Gildeprint Drukkerijen. <https://doi.org/10.26481/dis.20220223en>

## Document status and date:

Published: 01/01/2022

## DOI:

[10.26481/dis.20220223en](https://doi.org/10.26481/dis.20220223en)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.



## **Impact**

Acknowledgements

Curriculum Vitae

List of publications

Ellis Nelissen

Approximately 50 million people suffer from dementia worldwide, and nearly 10 million new cases are diagnosed each year. By 2050, the number of dementia cases is expected to triple, leading to \$4 trillion in estimated costs worldwide. Indeed, in the US alone the economic costs of dementia rose from \$279.6 billion to \$984 billion between the years 2000 and 2016, while the highest economic burden can be found in Europe [1]. Out of all these dementia cases, 20% is diagnosed with pure vascular dementia, making it the second most common form of dementia, after Alzheimer's disease in Caucasian populations [2]. However, the broader term of vascular cognitive impairment (VCI) also describes mixed pathologies, including contributing factors of VCI within Alzheimer's disease. Therefore, the actual prevalence of VCI is difficult to estimate, yet is much higher than the 20% of pure vascular dementia cases. Symptoms of VCI include memory loss, confusion, disorientation, and symptoms of stroke.

So far, no treatments have been approved for vascular dementia. Preventative measures such as lifestyle interventions and blood pressure medication, but also symptomatic treatment with cognitive enhancers designed specifically for Alzheimer's disease have not proven clear efficacy. The life expectancy of people diagnosed with vascular dementia was found to be on average five years from the moment of diagnosis. In essence, this implies that a vascular dementia diagnosis means a 60% chance of death within five years while slowly losing more cognitive functions which significantly impairs daily living, with no treatments available whatsoever. Indeed, vascular dementia causes the most substantial loss in quality of life out of all dementia types [3]. Furthermore, it is defined by the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline as "clinically significant deficits of sufficient severity in at least 1 cognitive domain (deficits may be present in multiple domains) and severe disruption to activities of daily living" [4]. Together this implies that currently a VCI diagnosis is a verdict of a lower quality of life with a reduced life expectancy. This emphasizes the emotional burden of a VCI diagnosis, and that a treatment for VCI is truly needed.

Both the worldwide economic burden and the emotional burden for the patient really emphasize the need for treatments, yet there are none available. The results from this thesis provide mechanistic insights into the enzyme sGC and its potential as a pharmacological target for cognition enhancement (scientific utilization). As

illustrated in chapter 2, sGC is also a target for cardiovascular disease. This suggests that due to the memory enhancing effects of sGC stimulators and activators, targeting sGC with sGC modulators may in the future provide to be a promising treatment for VCI (commercial utilization), which patients are in dire need for (socio-economic utilization). Especially the effects on hippocampal plasticity of brain-penetrant sGC modulators in combination with potential vascular effects may help repair both the brain and the vasculature synergistically. Therefore, sGC modulators may not only provide a symptomatic treatment, i.e. cognition enhancement, but may also repair/prevent damage and treat VCI at the core of its processes. Many of the research described in this thesis was performed in collaboration with pharmaceutical companies (e.g. BAYER and Merck) that have a strong interest in sGC as a target, both as a treatment for cardiovascular disease and neurodegenerative disorders such as vascular dementia. In fact, the research performed with vericiguat was a successful collaboration between us at Maastricht University, researchers from BAYER, and researchers from Merck [5]. Additionally, the experiments performed with BAY-747 and runcaciguat were all in collaboration with BAYER. The promising memory enhancing effects of BAY-747 and runcaciguat have convinced BAYER to continue the collaboration and provide resources for further research into the development for these sGC modulators as a treatment for VCI. Therefore, the results within this thesis may provide the solid basis for future research which has all the elements that can actually help to reach the patient in the end.

## References

- [1] J. Xu, Y. Zhang, C. Qiu, F. Cheng, Global and regional economic costs of dementia: a systematic review, *The Lancet* 390 (2017) S47.
- [2] F.J. Wolters, M.A. Ikram, Epidemiology of Vascular Dementia, Arteriosclerosis, Thrombosis, and Vascular Biology 39 (2019) 1542-1549.
- [3] W. Moon, Quality of life and disease burden in patients with MCI and dementia, *Alzheimer's & Dementia* 16 (2020) e039199.
- [4] O.A. Skrobot, S.E. Black, C. Chen, C. DeCarli, T. Erkinjuntti, G.A. Ford, R.N. Kalaria, J. O'Brien, L. Pantoni, F. Pasquier, G.C. Roman, A. Wallin, P. Sachdev, I. Skoog, V. group, Y. Ben-Shlomo, A.P. Passmore, S. Love, P.G. Kehoe, Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study, *Alzheimers Dement* 14 (2018) 280-292.
- [5] E. Nelissen, E.K. Argyrousi, N.P. Van Goethem, F. Zhao, C.D.G. Hines, G. Swaminath, M. Gerisch, J. Hueser, P. Sandner, J. Prickaerts, Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume, *Biomedicine* 9 (2021) 1047.